17 November 2014 - Deborah Wilkes
Archived
Actavis is set to acquire Allergan in a US$66 billion cash and shares deal that appears to have ended Valeant Pharmaceuticals International's hostile bid for the US-based maker of Botox.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.